Nilotinib, an approved leukemia drug, inhibits Smoothened signaling in Hedgehog-dependent medulloblastoma
K. K. Chahal, J. Li, I. Kufareva, M. Parle, D. D. Durden, R. Wechsler-Reya, C. C. Chen, R. Abagyan
The paper shows Nilotinib inhibits Hedgehog signaling in medulloblastoma by directly targeting Smoothened, outperforming Vismodegib in cell lines and xenograft models.
bioRxiv · Mar 25, 2019Cancer Biology